In this webinar, Leticia Arrington (Merck) and Richard Franzese (Certara) discussed data considerations, analysis methods, and learnings from a recent network MBMA analysis of relevant endpoints in NP that will be used for general competitive landscaping questions to support Merck’s ongoing mission to develop better NP therapies.
Read MoreBuilding an MBMA Framework to Support Developing New Neuropathic Pain Drugs
0 comments.
Click here to read/write comments.
Topics: